Did Neumora beat or miss consensus estimates last quarter?

What guidance did Neumora's management provide for the next earnings period?

What were the key takeaways from Neumora's earnings call?

What is Neumora's gross profit margin?

What is the revenue and EPS growth rate for Neumora year over year?

What does Neumora do and what are its main business segments?

What is the market's earnings forecast for Neumora next quarter?

What factors drove the changes in Neumora's revenue and profit?

- **Obesity Focus Launch**: NMRA-215 prioritized for obesity with Phase I clinical studies set for Q1 2026, targeting the $4 billion obesity market.
- **Pipeline Momentum**: 6 clinical catalysts expected over 18 months, including NMRA-861 Phase I data (Q1 2026), navacaprant Phase III readouts (Q1/Q2 2026), and NMRA-511 agitation results (late 2025).
- **Financial Strength**: $217.6 million cash runway supports full pipeline through 2027, with 10% YoY net loss reduction.
- **Safety Assurance**: NMRA-861 and 898 M4 PAMs demonstrate no convulsions in preclinical studies, resolving prior safety concerns.

**【CEO Summary Section】**
- Emphasized Neumora's mission to address large population health challenges through innovative neuroscience therapies.
- Announced prioritization of obesity as the lead indication for NMRA-215, a brain-penetrant NLRP3 inhibitor, targeting the unmet need for efficacious, well-tolerated obesity treatments.
- Highlighted the global obesity market (2.5 billion people in 2025, projected to 4 billion by 2035) and limitations of current GLP-1 therapies (68% discontinuation rate within 1 year).
- Expected to initiate clinical studies for NMRA-215 in Q1 2026 following preclinical DIO model data this fall.

**【President's Pipeline Update】**
- NMRA-861 (M4 PAM) Phase I study initiated in Q2 2025, with SAD/MAD data expected in Q1 2026.
- Navacaprant Phase III KOASTAL program progressing with top-line data from KOASTAL-3 (Q1 2026) and KOASTAL-2 (Q2 2026).
- NMRA-511 Phase Ib Alzheimer's agitation data expected late 2025.
- NMRA-215 preclinical DIO model results anticipated in Q4 2025, with clinical studies to begin Q1 2026.

**【Clinical Program Details】**
- NMRA-861: Highly potent, selective M4 PAM with best-in-class CNS penetration; Phase I study evaluating safety, PK, and efficacy in schizophrenia.
- Navacaprant: Enhanced medical monitoring and site selection in KOASTAL program; male/female enrollment reflects MDD prevalence.
- NMRA-511: Signal-seeking study in Alzheimer's agitation with CMAI as primary endpoint; not powered for statistical significance but informative for future development.

**【Financial Summary】**
- Q2 2025 cash balance: $217.6 million, supporting operations into 2027.
- Total net loss: $52.7 million (down 10% YoY) due to reduced stock-based compensation and clinical costs.
- Runway fully funds all key programs through clinical milestones, including NMRA-215, 861, navacaprant, and 511.

**【Q&A Highlights】**
- NMRA-215 preclinical DIO study will test monotherapy, GLP-1 combination, and maintenance therapy; expects to demonstrate superior CNS penetration vs competitors.
- M4 PAMs (861, 898) structurally distinct from 266, with no convulsions observed in rabbit studies at doses exceeding 266's threshold.
- KOASTAL program improvements include verified clinical trials database and reduced site count; enrollment reflects real-world MDD demographics.
- Obesity program confidence stems from CNS expertise and NLRP3's novel mechanism; no current plans to partner before Phase I.

Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript

- **Pipeline Momentum**: 3 Phase 3 readouts (KOASTAL-3/Q1 2026, KOASTAL-2/Q2 2026, NMRA-511/Q4 2025) across MDD, AD Agitation, and M4 PAMs.
- **Financial Strength**: $249.4M cash + $125M debt facility extends runway to 2027, enabling multi-program execution.
- **Navacaprant Strategy**: Enhanced patient screening reduces noise, targeting 25% enrollment flexibility in Phase 3 studies.
- **Differentiation**: 100x higher kappa selectivity vs. J&J's aticaprant; NMRA-511 V1a antagonist addresses $2B AD agitation market with only 1 approved drug.


**【CEO Opening Remarks】**
- Highlighted the global brain disease crisis affecting 1.5 billion people, emphasizing the need for novel mechanisms in neuroscience drug development.
- Announced a strong financial foundation and upcoming clinical catalysts across the pipeline, positioning the company to redefine brain disease treatment.

**【President Business Update】**
- **NMRA-511 (Alzheimer's Agitation):** Phase 1b signal-seeking study expected to report data Q4 2025, targeting V1a receptor for agitation reduction with strong tolerability in Phase 1 trials.
- **Navacaprant (MDD):** KOASTAL-3 (Q1 2026) and KOASTAL-2 (Q2 2026) Phase 3 studies with enhanced patient screening (SAFER, Verified Clinical Trial DB) to ensure appropriate MDD population enrollment.
- **M4 PAM Franchise:** First candidate to enter clinic mid-2025, targeting improved safety/tolerability with once-daily dosing.
- Secured $125M debt facility with K2 HealthVentures, extending cash runway into 2027.

**【COO Clinical Program Details】**
- **Navacaprant Adjustments:** 25% enrollment flexibility in KOASTAL-2/3, enhanced medical monitoring, and exclusion of multi-trial participants to improve data reliability.
- **Competitive Differentiation:** Navacaprant's 100x higher kappa/mu receptor selectivity vs. J&J's aticaprant, supporting monotherapy efficacy.
- **NMRA-511 Mechanism:** V1a antagonist reduces aggression/anxiety in preclinical models, addressing AD agitation with only one approved agent (AXS-05) carrying a black box warning.

**【CFO Financial Review】**
- Q1 2025 net loss: $68M (vs. $53.7M in Q1 2024), ending cash: $249.4M.
- $20M drawn from K2 facility, with $20M additional draw available this year, supporting operations into 2027.
- Disciplined capital allocation focused on high-value clinical milestones.

**【Q&A Highlights】**
- **Navacaprant Enrollment:** SAFER and Verified DB tools exclude 10-15% of potential patients, maintaining enrollment pace without delays.
- **K2 Financing Flexibility:** Additional $20M draw possible this year, with debt repayment tied to future milestones.
- **M4 PAM Differentiation:** Focus on CNS penetration to mitigate cardiovascular AEs seen with emraclidine.
- **Competitor Comparison:** AXS-05's Phase 3 data showed 29% response rate vs. navacaprant's Phase 2 45% reduction in anhedonia, supporting novel mechanism potential.


Neumora Therapeutics, Inc. Common Stock (NMRA)-12 May 25-2025 Q1 Earnings call transcript

- **Strong Financial Position:** $307.6M cash runway into mid-2026 supports 3 clinical-stage programs.
- **Navacaprant Phase 3 Adjustments:** Enhanced patient screening (SAFER, VCT) and site reduction to address KOASTAL-1 placebo anomaly; data expected Q1/Q2 2026.
- **NMRA-511 Progress:** Alzheimer's agitation Phase 1b study ongoing; M4 PAM compound to enter clinic mid-2025.
- **Cash Management:** No immediate financing needs despite tight readout timeline; strategic funding options available.

**【CEO Opening Remarks】**
- Neumora has a strong financial position with $307.6M in cash as of Q4 2024, supporting operations into mid-2026.
- The pipeline includes 7 programs targeting novel mechanisms in brain diseases, with 3 in clinical stages.
- 2025 priorities: advancing navacaprant Phase 3 studies (KOASTAL-2/3), NMRA-511 Phase 1b in Alzheimer's agitation, and M4 PAM compounds into the clinic.

**【Josh Pinto - Pipeline Updates】**
- **Navacaprant (KOASTAL Program):**
  - Phase 3 studies paused post-KOASTAL-1 failure; resumed with enhanced patient screening (SAFER review, VCT database) and reduced clinical sites.
  - Expected top-line data: KOASTAL-3 (Q1 2026), KOASTAL-2 (Q2 2026).
  - Bipolar depression trial discontinued to focus resources on MDD program.
- **NMRA-511:** Phase 1b signal-seeking study in Alzheimer's agitation; results expected late 2025.
- **M4 Franchise:** Next compound to enter clinic mid-2025, targeting improved safety/tolerability vs. atropine.

**【Bill Aurora - Clinical Program Details】**
- **KOASTAL-1 Key Learnings:**
  - 14-point placebo response in males vs. 6.5 in females; sites with prior positive MDD trial experience performed better.
  - Adjustments for KOASTAL-2/3: SAFER medical review, VCT database screening, reduced sites (focus on high-experience centers).
- **NMRA-511:** V1a receptor antagonist with strong preclinical agitation reduction data; Phase 1b evaluating safety/tolerability.
- **Preclinical Pipeline:** 4 programs targeting Alzheimer's, schizophrenia, Parkinson's, and ALS.

**【Michael Milligan - Financials】**
- Q4 2024 operating expenses: $58.8M (vs. $108.7M in 2023 Q4); full year 2024: $243.8M (vs. $235.9M in 2023).
- Cash runway supports operations into mid-2026; no immediate financing needs despite tight timeline for KOASTAL readouts.

**【Q&A Highlights】**
- **KOASTAL-2/3 Enrollment:** No patient count disclosure, but studies sized for 332 patients each; adjustments may allow 25% enrollment increase if needed.
- **M4 Franchise Update:** Follow-on compounds de-risked for convulsions seen in NMRA-266; next compound to enter clinic mid-2025.
- **FDA Interactions:** No interim analyses planned; potential regulatory discussions pending KOASTAL-2/3 results.


Actual	-0.71	-0.37	-0.45	-0.37	-0.42	-0.33	-0.35
Forecast	-0.5512	-0.372	-0.3905	-0.424	-0.3736	-0.3626	-0.333	-0.3258
Surprise	-28.81%	+0.54%	-15.24%	+12.74%	-12.42%	+8.99%	-5.11%	0.00%

Actual	0	0	0	0	0	0	0	--
Forecast	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

NMRA

NMRA fundamentals

NMRA Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

NMRA

NMRA fundamentals

NMRA Q4 2025 Earnings Preview

Earnings Call

NMRA Earnings Call Summary for Q4/2025Upcoming8:00 AM on Mar 30, 2026

NMRA Earnings Call Summary for Q3/2025 Mar 28, 2026

NMRA Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

NMRA Earnings Call Summary for Q1/20254:30 PM on May 12, 2025

NMRA Earnings Call Summary for Q4/20248:00 AM on Mar 3, 2025

You can ask Aime